These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26482376)

  • 21. Granulocyte-colony stimulating factor for large anterior ST-elevation myocardial infarction: rationale and design of the prospective randomized phase III STEM-AMI OUTCOME trial.
    Achilli F; Malafronte C; Cesana F; Maggiolini S; Mauro C; De Ferrari GM; Lenatti L; Tespili M; Pasqualini P; Gentile F; Capogrossi MC; Maggioni A; Maseri A; Pontone G; Colombo GI; Pompilio G;
    Am Heart J; 2015 Oct; 170(4):652-658.e7. PubMed ID: 26386788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of CMR Markers of Myocardial Injury in Predicting LV Functional Recovery: Results from PROTECTION AMI CMR Sub-study.
    Grover S; Bell G; Lincoff M; Jeorg L; Madsen PL; Huang S; Leow S; Figtree G; Chakrabarty A; Leong DP; Woodman RJ; Selvanayagam JB
    Heart Lung Circ; 2015 Sep; 24(9):891-7. PubMed ID: 25846255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.
    Traverse JH; Henry TD; Moye' LA
    Am Heart J; 2011 Oct; 162(4):671-7. PubMed ID: 21982659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EARLY β-blocker administration before primary PCI in patients with ST-elevation myocardial infarction trial.
    Roolvink V; Rasoul S; Ottervanger JP; Dambrink JH; Lipsic E; van der Horst IC; de Smet B; Kedhi E; Marcel Gosselink AT; Piek JJ; Sanchez-Brunete V; Ibanez B; Fuster V; Van't Hof AW;
    Am Heart J; 2014 Nov; 168(5):661-6. PubMed ID: 25440793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial.
    Rao SV; Zeymer U; Douglas PS; Al-Khalidi H; Liu J; Gibson CM; Harrison RW; Joseph DS; Heyrman R; Krucoff MW
    Am Heart J; 2015 Nov; 170(5):929-37. PubMed ID: 26542501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trial.
    Leone AM; D'Amario D; Teofili L; Basile E; Cannata F; Graziani F; Marzilli M; Russo AM; Tarantini G; Ceconi C; Leone G; Trani C; Rebuzzi AG; Crea F
    Trials; 2016 Feb; 17():97. PubMed ID: 26891753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).
    Abbate A; Kontos MC; Grizzard JD; Biondi-Zoccai GG; Van Tassell BW; Robati R; Roach LM; Arena RA; Roberts CS; Varma A; Gelwix CC; Salloum FN; Hastillo A; Dinarello CA; Vetrovec GW;
    Am J Cardiol; 2010 May; 105(10):1371-1377.e1. PubMed ID: 20451681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Nozue T; Yamada M; Tsunoda T; Katoh H; Ito S; Iwaki T; Michishita I
    Heart Vessels; 2016 Aug; 31(8):1239-46. PubMed ID: 26293570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
    Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
    Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
    Hudson MP; Armstrong PW; Ruzyllo W; Brum J; Cusmano L; Krzeski P; Lyon R; Quinones M; Theroux P; Sydlowski D; Kim HE; Garcia MJ; Jaber WA; Weaver WD
    J Am Coll Cardiol; 2006 Jul; 48(1):15-20. PubMed ID: 16814643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computer-assisted quantification of myocardial reperfusion after primary percutaneous coronary intervention predicts functional and contrast-enhanced cardiovascular magnetic resonance outcomes in patients with ST-segment elevation myocardial infarction.
    Gu YL; Haeck JD; Vogelzang M; Bilodeau L; Krucoff MW; Tijssen JG; de Winter RJ; Zijlstra F; Koch KT
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):174-81. PubMed ID: 20518003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty.
    Liistro F; Grotti S; Angioli P; Falsini G; Ducci K; Baldassarre S; Sabini A; Brandini R; Capati E; Bolognese L
    Circ Cardiovasc Interv; 2009 Oct; 2(5):376-83. PubMed ID: 20031746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploration of Multiple Signaling Pathways Through Which Sodium Tanshinone IIA Sulfonate Attenuates Pathologic Remodeling Experimental Infarction.
    Mao S; Vincent M; Chen M; Zhang M; Hinek A
    Front Pharmacol; 2019; 10():779. PubMed ID: 31354493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left Ventricular Thrombus Formation After ST-Segment-Elevation Myocardial Infarction: Insights From a Cardiac Magnetic Resonance Multicenter Study.
    Pöss J; Desch S; Eitel C; de Waha S; Thiele H; Eitel I
    Circ Cardiovasc Imaging; 2015 Oct; 8(10):e003417. PubMed ID: 26481162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial.
    Ince H; Petzsch M; Kleine HD; Eckard H; Rehders T; Burska D; Kische S; Freund M; Nienaber CA
    Circulation; 2005 Aug; 112(9 Suppl):I73-80. PubMed ID: 16159869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial).
    Mewton N; Cung TT; Morel O; Cayla G; Bonnefoy-Cudraz E; Rioufol G; Angoulvant D; Guerin P; Elbaz M; Delarche N; Coste P; Vanzetto G; Metge M; Aupetit JF; Jouve B; Motreff P; Tron C; Labeque JN; Steg PG; Cottin Y; Range G; Clerc J; Coussement P; Prunier F; Moulin F; Roth O; Belle L; Dubois P; Barragan P; Gilard M; Piot C; Colin P; Morice MC; Monassier JP; Ider O; Dubois-Randé JL; Unterseeh T; Lebreton H; Beard T; Blanchard D; Grollier G; Malquarti V; Staat P; Sudre A; Hansson MJ; Elmer E; Boussaha I; Jossan C; Torner A; Claeys M; Garcia-Dorado D; Ovize M;
    Am Heart J; 2015 Jun; 169(6):758-766.e6. PubMed ID: 26027612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
    Post S; Post MC; van den Branden BJ; Eefting FD; Goumans MJ; Stella PR; van Es HW; Wildbergh TX; Rensing BJ; Doevendans PA
    Catheter Cardiovasc Interv; 2012 Nov; 80(5):756-65. PubMed ID: 22419603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction.
    Eitel I; de Waha S; Wöhrle J; Fuernau G; Lurz P; Pauschinger M; Desch S; Schuler G; Thiele H
    J Am Coll Cardiol; 2014 Sep; 64(12):1217-26. PubMed ID: 25236513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen".
    Bruder O; Breuckmann F; Jensen C; Jochims M; Naber CK; Barkhausen J; Erbel R; Sabin GV;
    Herz; 2008 Mar; 33(2):136-42. PubMed ID: 18344033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distal protection device aggravated microvascular obstruction evaluated by cardiac MR after primary percutaneous intervention for ST-elevation myocardial infarction.
    Yoon CH; Chung WY; Suh JW; Cho YS; Youn TJ; Chun EJ; Choi SI; Chae IH; Choi DJ
    Int J Cardiol; 2013 Sep; 167(5):2002-7. PubMed ID: 22633663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.